Lili Du
The University of Texas MD Anderson Cancer Center(US)Shanghai Jiao Tong University(CN)Shanghai Chest Hospital(CN)Third Affiliated Hospital of Guangzhou Medical University(CN)Huzhou Central Hospital(CN)Liaocheng People's Hospital(CN)Guangzhou Medical University(CN)
Publications by Year
Research Areas
Molecular Biology Techniques and Applications, Breast Cancer Treatment Studies, Estrogen and related hormone effects, Melanoma and MAPK Pathways, Cancer Genomics and Diagnostics
Most-Cited Works
- → Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial(2021)308 cited
- → BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling(2013)80 cited
- → The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues(2019)63 cited
- → Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity(2016)61 cited
- → Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy(2021)45 cited
- → Hormonal modulation of ESR1 mutant metastasis(2020)42 cited